News

July 8, 2019

EIP Pharma Appoints Noel Donnelly as CFO

CAMBRIDGE, Mass., July 8, 2019 /PRNewswire/ — EIP Pharma, Inc. a CNS-focused therapeutics company, today announced that it has expanded its leadership team with the appointment of Noel Donnelly as CFO. Mr. Donnelly joins EIP Pharma from Takeda Pharmaceuticals where he led a group focused on strategy and operations.

“We are thrilled to welcome Noel to the EIP team at such an important time for the company,” said John Alam, CEO, EIP Pharma. “His expertise in life sciences finance, strategy and operations will be critical as we continue to advance our lead asset, neflamapimod, through Phase 2b in Alzheimer’s disease and in new indications.”

Mr. Donnelly is an executive with over 15 years of experience at Shire where he held positions of increasing responsibility and leadership in Finance and Research and Development (R&D). Prior to joining EIP, Noel spent the last seven years developing and leading a new strategic and operational function within Shire, a global biopharma recently acquired by Takeda Pharmaceuticals, which included R&D Strategy, Portfolio Management, Due Diligence, and Integrations. Before moving into R&D, Noel held a number of positions of increasing responsibility within the Finance organization in areas such as Commercial, Technical Operations, and ultimately as the Head of R&D Finance at Shire HGT. Prior to that Noel worked for twelve years in financial planning and analysis in financial services and industrial companies. Noel received his MBA from Babson College and B.S in Nuclear Engineering from UMass-Lowell.